UniSuper Management 13F: Adds $23M to AbbVie (ABBV) Stake
Key Points
- UniSuper Management increased its stake in AbbVie by 86,423 shares, a 23.4% rise, as reported in its latest 13F filing.
- The fund now holds 456,240 shares of AbbVie, representing 1.04% of its total portfolio valued at about $11.5 billion.
- AbbVie shares recently traded around $286.74, which is above both the 50-day and 200-day moving averages.
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
On October 26, 2026, UniSuper Management boosted its stake in AbbVie Inc. (ABBV) by 86,423 shares, increasing its total ownership to 456,240 shares worth approximately $119.3 million. This information comes from the fund's latest Form 13F filing with the SEC.
In its filing, UniSuper Management reported a 23.4% increase in its position in AbbVie, which indicates a growing confidence in the company. The fund's reported value for this position is $11,488,756,270, and AbbVie ranks 17th out of 636 positions in UniSuper's portfolio.
ABBV
AbbVie Inc.
UniSuper Management vs. the S&P 500
Hypothetical returns from UniSuper Management's disclosed trades, not real profit or advice. How we model this.
Where AbbVie Fits in UniSuper Management's Portfolio
AbbVie's position makes up 1.04% of UniSuper's total portfolio. The recent increase adds a significant amount to their holdings, reflecting an estimated gain based on current prices.
AbbVie Inc. Stock Up 0.4%
AbbVie shares closed at $285.64 on October 23, 2026, and as of October 27, 2026, they recently traded around $286.74, which is above both the 50-day and 200-day moving averages. The stock is currently about 1.6% below its 52-week high of $291.40, indicating it has been performing well.
Recent Earnings
AbbVie reported trailing twelve-month revenue of about $64.4 billion, showing a year-over-year growth of 10.2%. The company is scheduled to announce its next earnings on October 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie has an annual dividend rate of $6.92, which gives it a yield of 2.42%. The dividend payout ratio is notably high at 190.4%.
Insider Buying and Selling at AbbVie Inc.
Several insiders have sold shares recently, including Perry C. Siatis, General Counsel, who sold 22,381 shares at $230.00 each on February 25, 2026, for a total value of about $5.1 million. This was followed by additional sales from Siatis and others in March and August.
Analysts Set New Price Targets
On October 9, 2026, UBS maintained a Neutral rating for AbbVie with a target price of $275. On the same day, Guggenheim reiterated a Buy rating, also maintaining a price target of $288. RBC Capital followed with an Outperform rating and a target of $280 on October 13. Barclays set an Overweight rating with a target of $325 on October 21, while Goldman Sachs maintained a Neutral rating with a target of $294 on October 23.
About AbbVie Inc.
AbbVie Inc. is a research-based biopharmaceutical company that develops and sells a variety of medicines and therapies worldwide. The company focuses on treatments for autoimmune diseases, blood cancers, and other serious conditions. This recent increase in ownership by UniSuper Management suggests a positive outlook on AbbVie’s ongoing product developments and market position.
Bottom Line
Investors will be watching AbbVie closely as it approaches its next earnings report on October 30, 2026. UniSuper Management's increased stake could signal confidence in the company’s future performance.
Related Filing Alerts
Source: UniSuper Management's 13F filing on $ABBV (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts